Patil, Hemant and Spoorthy, Mamidipalli Sai (2021) Post-COVID- 19 Mucormycosis: A Review. Journal of Pharmaceutical Research International, 33 (61A). pp. 101-108. ISSN 2456-9119
5463-Article Text-7593-1-10-20221006.pdf - Published Version
Download (539kB)
Abstract
Background and Aims: After being affected by a severe second wave of COVID-19 with numerous cases and deaths, India is now facing new challenges due to the disease. One of these is the feared complication of rhino-orbital mucormycosis in post-infectious individuals. Case reports and research studies on this association are on the rise. Our goal is to conduct a comprehensive literature review to evaluate the distinctiveness of individuals with mucormycosis and COVID-19.
Methods: A literature search was done on the following databases: PubMed, Google Scholar, and Cochrane Library using the following keywords like COVID 19, Mucormycosis, Mucor, Novel coronavirus, and SARS CoV-2, a systematic.
Results: Studies have shown that history of diabetes mellitus and steroid treatments were the common possible factors for the increased post-covid-19 mucormycosis. Hyperglycemia secondary to uncontrolled hyperglycemic states like DM and immunosuppression secondary to covid-19 infection, steroid use form a vicious cycle causing mucormycosis.
Conclusion: Increased incidence of mucormycosis in India post-COVID infection appears to be due to a triad of diabetes, irrational steroid use, and COVID-19 itself. To decrease the frequency of deadly mucormycosis in patients with COVID-19, all attempts should be made to preserve optimal sugar levels in the body, and the use of corticosteroids should be restricted and should be given as per recommended by ICMR.
Item Type: | Article |
---|---|
Subjects: | East Asian Archive > Medical Science |
Depositing User: | Unnamed user with email support@eastasianarchive.com |
Date Deposited: | 20 Feb 2023 10:31 |
Last Modified: | 28 May 2024 05:55 |
URI: | http://library.eprintdigipress.com/id/eprint/145 |